The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LLY | +31.59% | +658.82% | +49.91% | +168,084% |
| S&P | +13.19% | +87.83% | +13.42% | +8,993% |
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
These top growth stocks have plenty of room left to run.
Healthcare stocks have plenty to offer new investors.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $17.60B | 53.9% |
| Gross Profit | $14.59B | 57.4% |
| Gross Margin | 82.91% | 1.9% |
| Market Cap | $722.15B | -14.2% |
| Market Cap / Employee | $15.36M | 0.0% |
| Employees | 47K | 9.3% |
| Net Income | $5.58B | 475.3% |
| EBITDA | $8.86B | 80.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.79B | 190.6% |
| Accounts Receivable | $16.11B | 56.5% |
| Inventory | 12.2K | 63.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $40.87B | 40.7% |
| Short Term Debt | $1.63B | -21.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 19.33% | 6.8% |
| Return On Invested Capital | 23.64% | -0.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $6.75B | 185.8% |
| Operating Free Cash Flow | $8.84B | 138.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 67.19 | 68.42 | 51.69 | 37.74 | -61.06% |
| Price to Book | 51.51 | 55.14 | 46.88 | 39.54 | -36.35% |
| Price to Sales | 16.24 | 15.18 | 13.17 | 11.54 | -41.18% |
| Price to Tangible Book Value | 379.24 | 346.97 | 185.60 | 109.56 | -84.94% |
| Price to Free Cash Flow TTM | 168.70 | - | |||
| Enterprise Value to EBITDA | 123.53 | 135.17 | 98.39 | 81.12 | -52.06% |
| Free Cash Flow Yield | 0.6% | - | |||
| Return on Equity | 84.8% | 77.7% | 86.7% | 96.8% | 47.26% |
| Total Debt | $33.64B | $38.52B | $39.90B | $42.51B | 36.59% |
There are new ways to tackle weight loss, but the stocks leading the way are lagging.
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?
The great buildout for AI and GLP-1 drugs continues.
LLY earnings call for the period ending December 31, 2024.
LLY earnings call for the period ending September 30, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
